Deal could put FDA reps in China

Share this article:

A deal between the US and China could mean more FDA inspection of manufacturing plants. Regulatory Focus reports that the countries struck a deal Dec. 5 that officials say will mean “a substantial increase in the number of US food and drug inspectors” on site.

The news could mean a new rash of Warning Letters to read up on: RF notes that on-site inspections in India, for example, netted six Warning Letters in 2012, and inspectors also put a dent in businesses including Wockhardt and Fresenius Kabi, after finding problems with their facilities.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters